| SEQ_NO | 2 | Date of announcement | 2025/04/23 | Time of announcement | 16:55:49 |
| Subject | Announcement of Medeon’s fund loans and over-limit improvement plan | ||||
| Date of events | 2025/04/23 | To which item it meets | paragraph 53 | ||
| Statement | 1.Date of occurrence of the event:2025/04/23 2.Company name:Medeon Biodesign, Inc. 3.Relationship to the Company (please enter ‘head office’ or ‘subsidiaries’):Head office 4.Reciprocal shareholding ratios:NA 5.Cause of occurrence: Due to the decrease in net worth reported in the audited financial statements for the fourth quarter of 2024, the amount of the Company’s loan to its subsidiary, PMC, has exceeded the limit for loans to a single entity. 6.Countermeasures: PMC is currently conducting a cash capital increase by issuing 4,125,000 shares of Series E preferred stock, with a target fundraising amount of NT$330,000,000. Upon completion of the capital increase, the company plans to repay the principal and interest to Medeon at an annual interest rate of 3%. Medeon thereby resolves the issue of exceeding the loan limit for a single entity. 7.Any other matters that need to be specified(the information disclosure also meets the requirements of Article 7, subparagraph 9 of the Securities and Exchange Act Enforcement Rules, which brings forth a significant impact on shareholders rights or the price of the securities on public companies.):None |
||||